Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.30 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2283238 | 1.00 | ALDH1A1 (0.38) | ALDH1A1PKMSLC1A2KMT2AATM | |
| SCHEMBL2685780 | 0.85 | SLC1A2 (0.35) | ALDH1A1PKMSLC1A2 | |
| SCHEMBL7202399 | 0.74 | ALDH1A1 (0.46) | ALDH1A1PKMSLC1A2KMT2ACYP2D6 | |
| SCHEMBL7202403 | 0.74 | ALDH1A1 (0.46) | ALDH1A1PKMSLC1A2KMT2ACYP2D6 | |
| SCHEMBL2913715 | 0.73 | KMT2A (0.42) | ALDH1A1PKMSLC1A2KMT2AATM | |
| SCHEMBL7754082 | 0.72 | CYP2D6 (0.30) | ALDH1A1PKMCYP2D6CYP2C9 | |
| SCHEMBL8583037 | 0.69 | ALDH1A1 (0.49) | ALDH1A1PKMSLC1A2KMT2AATM | |
| SCHEMBL4381247 | 0.69 | ALDH1A1 (0.49) | ALDH1A1PKMSLC1A2KMT2AATM | |
| SCHEMBL1564214 | 0.69 | KMT2A (0.53) | ALDH1A1PKMSLC1A2KMT2AATM | |
| SCHEMBL57078 | 0.69 | KMT2A (0.53) | ALDH1A1PKMSLC1A2KMT2AATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 4963 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122075736-A | Tumor microenvironment responsive enzyme prodrug conversion nano-composite and preparation method thereof | — | 2026-05-26 | — | — | CN | claimed |
| US-12605473-B2 | Methods for making radiolabeled anti-MET binding proteins | REGENERON PHARMACEUTICALS, INC. (US) | 2026-04-21 | — | — | US | claimed |
| EP-4649966-A2 | RADIOLABELED ANTI-PD-L1 ANTIBODIES FOR IMMUNO-PET IMAGING | Regeneron Pharmaceuticals, Inc. (US) | 2025-11-19 | — | — | EP | claimed |
| CN-120028537-A | Preparation method of low background value kit | 宁波瑞源生物科技有限公司 | 2025-05-23 | — | — | CN | claimed |
| CN-119470882-B | Enzyme-labeled secondary antibody polymer for immunohistochemical staining | 百盛(广州)生物制品有限公司 | 2025-04-11 | — | — | CN | claimed |
| WO-2025040093-A1 | MOLECULAR PROBES TARGETING GPC3 AND USE THEREOF | 武汉睿迪辐生物科技有限公司 | 2025-02-27 | — | — | WO | claimed |
| CN-119499408-A | Molecular probes targeting GPC3 and uses | 武汉睿迪辐生物科技有限公司 | 2025-02-25 | — | — | CN | claimed |
| CN-119470882-A | Enzyme-labeled secondary antibody polymer for immunohistochemical staining | 百盛(广州)生物制品有限公司 | 2025-02-18 | — | — | CN | claimed |
| US-20240409637-A1 | ANTI-CD8 ANTIBODIES AND USES THEREOF | REGENERON PHARMACEUTICALS, INC. | 2024-12-12 | — | — | US | claimed |
| CN-112423784-B | Immunogenic products comprising IL-4 and/or IL-13 for treating disorders associated with aberrant IL-4 and/or IL-13 expression or activity | 尼奥瓦克斯公司 | 2024-09-20 | — | — | CN | claimed |
| EP-1118334-A1 | Method for the production of conjugates and uses thereof for the prevention and treatment of allergic reactions and autoimmune diseases | Aventis Behring Gesellschaft mit beschränkter Haftung (DE) | 2001-07-25 | — | — | EP | claimed |
| US-20010007755-A1 | Method for the production of conjugates and uses thereof for the prevention and treatment of allergic reactions and autoimmune diseases | TOLEROGEN LTD. (CH) | 2001-07-12 | — | — | US | claimed |
| EP-0699068-A1 | REDUCTION OF LIPOSOME-INDUCED ADVERSE PHYSIOLOGICAL REACTIONS | THE LIPOSOME COMPANY, INC. (US) | 1996-03-06 | — | — | EP | claimed |
| WO-1994027580-A1 | REDUCTION OF LIPOSOME-INDUCED ADVERSE PHYSIOLOGICAL REACTIONS | THE LIPOSOME COMPANY, INC. (US) | 1994-12-08 | — | — | WO | claimed |
| EP-0595863-A1 | IMPLANT MATERIALS | BRITISH TECHNOLOGY GROUP LTD (GB) | 1994-05-11 | — | — | EP | claimed |
| EP-0366770-B1 | LIPOSOMES COUPLED TO HORMONES | VESTAR INC (US) | 1994-02-09 | — | — | EP | claimed |
| US-5258499-A | Liposome targeting using receptor specific ligands | VESTAR, INC. (US) | 1993-11-02 | — | — | US | claimed |
| WO-1993000935-A1 | IMPLANT MATERIALS | BRITISH TECHNOLOGY GROUP LTD. (GB) | 1993-01-21 | — | — | WO | claimed |
| EP-0366770-A1 | LIPOSOMES COUPLED TO HORMONES. | SANDOZ AG (CH) | 1990-05-09 | — | — | EP | claimed |
| WO-1989011270-A1 | LIPOSOMES COUPLED TO HORMONES | SANDOZ AG (CH) | 1989-11-30 | — | — | WO | claimed |